Argenx acquires Forte Biosciences for 2.2 billion dollars to bolster autoimmune portfolio

Summary

The Belgian-Dutch pharmaceutical giant Argenx has reached a definitive agreement to acquire Forte Biosciences, securing FB-102, a promising anti-CD122 monoclonal antibody targeted at refractory autoimmune conditions impacting women disproportionately.

Positioning inside the women's health category is being redrawn — the interesting question is which adjacent operators reprice. Look for follow-on moves from named investors, incumbents, and new entrants in the lane.

Sources

• OVUM Primary source